North America Human Insulin 麻豆原创 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0120046

Publication Date:

January 18, 2020

Pages:

105

Publisher:

Grace 麻豆原创 Data

Countries:

North America [1]

USD 2,480.00

Pharmaceutical Manufacturing [2]

Country Overview (Pharma & Healthcare) [3]

Pharma & Healthcare [4]

Description:

North America human insulin market is expected to reach $23.52 billion by 2025, growing by 7.36% annually over the next years.
Highlighted with 27 tables and 52 figures, this 105-page report 鈥淣orth America Human Insulin 麻豆原创 2020-2026 by Product Type (Drugs, Delivery Devices), Application (Type 1 Diabetes, Type 2 Diabetes, Others), Distribution Channel, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire North America human insulin market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. In this report 2019 is the base year for market analysis, with estimates and forecast covering 2020-2026. (Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view. The balanced (most likely) projection is used to quantify North America human insulin market in every aspect of the classification from perspectives of Product Type, Application, Distribution Channel, and Country.
Based on product type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
鈥� Human Insulin Drugs
鈥� Human Insulin Delivery Devices
Based on product, the North America Human Insulin Drugs market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
鈥� Modern Human Insulin (further segmented into Long-acting, Rapid- acting, Premixed by type; further segmented into Lantus, Apidra, Levemir, NovoRapid/ NovoLog, Novomix, Humalog, Others by brand)
鈥� Traditional Human Insulin (further segmented into Short-acting, Intermediate & Rapid-acting, Premixed by type; further segmented into Humulin, Insuman, Novolin/Actrapid/Insulatard by brand)
Based on product, the North America Human Insulin Delivery Devices market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
鈥� Syringes
鈥� Pens (further segmented into Disposable, Reusable, Pen needles)
鈥� Pumps
鈥� Others
Based on application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
鈥� Type 1 Diabetes
鈥� Type 2 Diabetes
鈥� Gestational Diabetes and Prediabetes
Based on distribution channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2026 included in each section.
鈥� Hospital Pharmacies
鈥� Retail Pharmacies
鈥� Online Pharmacies
Geographically, the following national/local markets are fully investigated:
鈥� U.S.
鈥� Canada
For each of the aforementioned countries, market analysis and revenue data are available for 2019-2026. The breakdown of major national markets by Product Type, Application, and Distribution Channel over the study years (2019-2026) is included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America human insulin market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players:
Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt
(Please Note: The report will be updated before delivery to make sure that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 5
1.1 Industry Definition and Research Scope 5
1.1.1 Industry Definition 5
1.1.2 Research Scope 6
1.2 Research Methodology 8
1.2.1 Overview of 麻豆原创 Research Methodology 8
1.2.2 麻豆原创 Assumption 9
1.2.3 Secondary Data 9
1.2.4 Primary Data 9
1.2.5 Data Filtration and Model Design 10
1.2.6 麻豆原创 Size/Share Estimation 11
1.2.7 Research Limitations 12
1.3 Executive Summary 13
2 麻豆原创 Overview and Dynamics 15
2.1 麻豆原创 Size and Forecast 15
2.2 Major Growth Drivers 16
2.3 麻豆原创 Restraints and Challenges 19
2.4 Emerging Opportunities and 麻豆原创 Trends 22
2.5 Porter鈥檚 Fiver Forces Analysis 25
3 Segmentation of North America 麻豆原创 by Product Type 29
3.1 麻豆原创 Overview by Product Type 29
3.2 Human Insulin Drugs 31
3.3 Human Insulin Delivery Devices 32
4 Segmentation of North America Human Insulin Drugs 麻豆原创 by Drug Product 33
4.1 麻豆原创 Overview by Drug Product 33
4.2 Modern Human Insulin 35
4.2.1 Modern Human Insulin by Type 37
4.2.2 Modern Human Insulin by Brand 41
4.3 Traditional Human Insulin 48
4.3.1 Traditional Human Insulin by Type 50
4.3.2 Traditional Human Insulin by Brand 53
5 Segmentation of North America Human Insulin Delivery Devices 麻豆原创 by Device Product 56
5.1 麻豆原创 Overview by Product 56
5.2 Syringes 58
5.3 Pens 59
5.4 Pumps 60
5.5 Other Devices 62
6 Segmentation of North America 麻豆原创 by Application 63
6.1 麻豆原创 Overview by Application 63
6.2 Type 1 Diabetes 65
6.3 Type 2 Diabetes 66
6.4 Gestational Diabetes and Prediabetes 67
7 Segmentation of North America 麻豆原创 by Distribution Channel 68
7.1 麻豆原创 Overview by Distribution Channel 68
7.2 Hospital Pharmacies 70
7.3 Retail Pharmacies 71
7.4 Online Pharmacies 72
8 North America 麻豆原创 2019-2026 by Country 73
8.1 Overview of North America 麻豆原创 73
8.2 U.S. 麻豆原创 76
8.3 Canadian 麻豆原创 80
9 Competitive Landscape 82
9.1 Overview of Key Vendors 82
9.2 New Product Launch, Partnership, Investment, and M&A 86
9.3 Company Profiles 88
Astra Zeneca PLC 88
Biocon 90
Eli Lilly 91
Exir 92
Julphar 93
Novo Nordisk AS 94
Pfizer 95
Sanofi Aventis 96
Sedico 97
Wockhardt 98
10 Investing in North America 麻豆原创: Risk Assessment and Management 99
10.1 Risk Evaluation of North America 麻豆原创 99
10.2 Critical Success Factors (CSFs) 102
Related Reports and Products 105

Companies Mentioned:

Astra Zeneca PLC
Biocon
Eli Lilly
Exir
Julphar
Novo Nordisk AS
Pfizer
Sanofi Aventis
Sedico
Wockhardt

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.